Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Catalyst Pharmaceuticals (CPRX) Shares Outstanding (2016 - 2026)

Catalyst Pharmaceuticals filings provide 17 years of Shares Outstanding readings, the most recent being $122.2 million for Q1 2026.

  • On a quarterly basis, Shares Outstanding changed 0.18% to $122.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $122.2 million, a 0.18% change, with the full-year FY2025 number at $122.5 million, up 1.35% from a year prior.
  • Shares Outstanding hit $122.2 million in Q1 2026 for Catalyst Pharmaceuticals, roughly flat from $122.5 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $123.3 million in Q3 2025 to a low of $102.7 million in Q2 2022.
  • Median Shares Outstanding over the past 5 years was $118.0 million (2024), compared with a mean of $113.5 million.
  • Biggest five-year swings in Shares Outstanding: decreased 0.82% in 2022 and later grew 12.84% in 2024.
  • Catalyst Pharmaceuticals' Shares Outstanding stood at $105.3 million in 2022, then increased by 1.77% to $107.1 million in 2023, then grew by 12.84% to $120.9 million in 2024, then grew by 1.35% to $122.5 million in 2025, then decreased by 0.27% to $122.2 million in 2026.
  • The last three reported values for Shares Outstanding were $122.2 million (Q1 2026), $122.5 million (Q4 2025), and $123.3 million (Q3 2025) per Business Quant data.